A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer
- 30 September 2013
- journal article
- research article
- Published by Elsevier BV in Lung Cancer
- Vol. 81 (3), 445-450
- https://doi.org/10.1016/j.lungcan.2013.06.025
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Abstract 4607: A translational study of Tumor Treating Fields in non small cell lung cancerCancer Research, 2012
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma.Journal of Clinical Oncology, 2010
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyThe Lancet, 2009
- Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerNew England Journal of Medicine, 2009
- Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)BMC Medical Physics, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumorsProceedings of the National Academy of Sciences of the United States of America, 2007
- Disruption of Cancer Cell Replication by Alternating Electric FieldsCancer Research, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004